Gauzy and Research Frontiers CEOs Discuss Smart Glass Technology in Benzinga All Access Interview
November 6, 2024
IPO: Jun 6, 24
Industry:
MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES
New York and Tel Aviv, Israel – Eyal Peso, CEO of Gauzy Ltd. (Nasdaq: GAUZ), and Joseph Harary, CEO of Research Frontiers Inc. (Nasdaq: REFR), recently participated in a joint interview with Benzinga All Access to discuss their companies’ partnership and the growing adoption of SPD-SmartGlass technology.
The interview focused on Ferrari’s recent selection of Gauzy as its strategic supplier for SPD technology, marking the first mass-production use of this innovative light-control technology in a Ferrari model. Peso and Harary highlighted the significant growth potential for smart glass, particularly in automotive, architectural, and aircraft applications. They emphasized the benefits of SPD technology, including enhanced comfort, safety, aesthetics, energy efficiency, and thermal comfort.
Gauzy, a strategic investor and licensee of Research Frontiers, is a leading provider of SPD technology, which uses nanoparticles to control light transmission through glass or plastic. This technology is already being used by several automotive manufacturers, including McLaren, Mercedes, and Cadillac, and is expected to see wider adoption in the future. The interview can be viewed online at https://www.youtube.com/watch?v=mFh46iIu2SE.
Fractyl Health to Present New Preclinical Data on its Gene Therapy Candidate at ObesityWeek 2024
November 4, 2024
IPO: Feb 2, 24
Industry:
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Burlington, Massachusetts – Fractyl Health, Inc. (Nasdaq: GUTS), a metabolic therapeutics company, will present new preclinical data on its Rejuva RJVA-001 pancreatic gene therapy candidate at ObesityWeek 2024 in San Antonio, Texas.
Rejuva is Fractyl’s adeno-associated virus (AAV)-based gene therapy program designed for durable pancreatic production of therapeutic peptides. RJVA-001 encodes a Smart GLP-1 for the treatment of Type 2 Diabetes. The presentation will include new results from preclinical studies in mice, demonstrating sustained weight loss and blood sugar control 13 weeks after treatment.
The data confirms the efficacy of RJVA-001 and highlights its potential as a durable, single-dose treatment option for obesity and Type 2 Diabetes. Fractyl also announced the nomination of RJVA-002, a GIP/GLP-1 dual agonist, as its first pancreatic gene therapy candidate for obesity.